Antiretroviral therapy in human immunodeficiency virus (HIV)-positive patients can induce a lipodystrophy syndrome of peripheral fat wasting and central adiposity, dyslipidemia, and insulin resistance. To test whether in this syndrome insulin resistance is associated with abnormal muscle handling of fatty acids, 12 HIV-1 patients (8 females/4 males, age = 26 ± 2 yr, HIV duration = 8 ± 1 yr, body mass index = 22.0 ± 1.0 kg/m2, on protease inhibitors and nucleoside analog RT inhibitors) and 12 healthy subjects were studied. HIV-1 patients had a total body fat content (assessed by dual-energy X-ray absorptiometry) similar to that of controls (22 ± 1 vs. 23 ± 2%; P = 0.56), with a topographic fat redistribution characterized by reduced fat content in the legs (18 ± 2 vs. 32 ± 3%; P < 0.01) and increased fat content in the trunk (25 ± 2 vs. 19 ± 2%; P = 0.03). In HIV-positive patients, insulin sensitivity (assessed by QUICKI) was markedly impaired (0.341 ± 0.011 vs. 0.376 ± 0.007; P = 0.012). HIV-positive patients also had increased total plasma cholesterol (216 ± 20 vs. 174 ± 9 mg/dl; P = 0.05) and triglyceride (298 ± 96 vs. 87 ± 11 mg/dl; P = 0.03) concentrations. Muscular triglyceride content assessed by means of 1H NMR spectroscopy was higher in HIV patients in soleus [92 ± 12 vs. 42 ± 5 arbitrary units (AU); P < 0.011 and tibialis anterior (26 ± 6 vs. 11 ± 3 AU; P = 0.04) muscles; in a stepwise regression analysis, it was strongly associated with QUICKI (R2 = 0.27; P < 0.0093). Even if the basal metabolic rate (assessed by indirect calorimetry) was comparable to that of normal subjects, postabsorptive lipid oxidation was significantly impaired (0.30 ± 0.07 vs. 0.88 ± 0.09 mg·kg-1·min-1; P ± 0.01). In conclusion, lipodystrophy in HIV-1 patients in antiretroviral treatment is associated with intramuscular fat accumulation, which may mediate the development of the insulin resistance syndrome

Luzi, L., Perseghin, G., Tambussi, G., Meneghini, E., Scifo, P., Pagliato, E., et al. (2003). Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. AMERICAN JOURNAL OF PHYSIOLOGY: ENDOCRINOLOGY AND METABOLISM, 284(2), E274-E280 [10.1152/ajpendo.00391.2001].

Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy

PERSEGHIN, GIANLUCA
Secondo
;
SCIFO, PAOLA VITTORIA;
2003

Abstract

Antiretroviral therapy in human immunodeficiency virus (HIV)-positive patients can induce a lipodystrophy syndrome of peripheral fat wasting and central adiposity, dyslipidemia, and insulin resistance. To test whether in this syndrome insulin resistance is associated with abnormal muscle handling of fatty acids, 12 HIV-1 patients (8 females/4 males, age = 26 ± 2 yr, HIV duration = 8 ± 1 yr, body mass index = 22.0 ± 1.0 kg/m2, on protease inhibitors and nucleoside analog RT inhibitors) and 12 healthy subjects were studied. HIV-1 patients had a total body fat content (assessed by dual-energy X-ray absorptiometry) similar to that of controls (22 ± 1 vs. 23 ± 2%; P = 0.56), with a topographic fat redistribution characterized by reduced fat content in the legs (18 ± 2 vs. 32 ± 3%; P < 0.01) and increased fat content in the trunk (25 ± 2 vs. 19 ± 2%; P = 0.03). In HIV-positive patients, insulin sensitivity (assessed by QUICKI) was markedly impaired (0.341 ± 0.011 vs. 0.376 ± 0.007; P = 0.012). HIV-positive patients also had increased total plasma cholesterol (216 ± 20 vs. 174 ± 9 mg/dl; P = 0.05) and triglyceride (298 ± 96 vs. 87 ± 11 mg/dl; P = 0.03) concentrations. Muscular triglyceride content assessed by means of 1H NMR spectroscopy was higher in HIV patients in soleus [92 ± 12 vs. 42 ± 5 arbitrary units (AU); P < 0.011 and tibialis anterior (26 ± 6 vs. 11 ± 3 AU; P = 0.04) muscles; in a stepwise regression analysis, it was strongly associated with QUICKI (R2 = 0.27; P < 0.0093). Even if the basal metabolic rate (assessed by indirect calorimetry) was comparable to that of normal subjects, postabsorptive lipid oxidation was significantly impaired (0.30 ± 0.07 vs. 0.88 ± 0.09 mg·kg-1·min-1; P ± 0.01). In conclusion, lipodystrophy in HIV-1 patients in antiretroviral treatment is associated with intramuscular fat accumulation, which may mediate the development of the insulin resistance syndrome
Articolo in rivista - Articolo scientifico
Human immunodeficiency virus; Biochemistry; Endocrinology; Physiology
English
2003
284
2
E274
E280
reserved
Luzi, L., Perseghin, G., Tambussi, G., Meneghini, E., Scifo, P., Pagliato, E., et al. (2003). Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. AMERICAN JOURNAL OF PHYSIOLOGY: ENDOCRINOLOGY AND METABOLISM, 284(2), E274-E280 [10.1152/ajpendo.00391.2001].
File in questo prodotto:
File Dimensione Formato  
AJP-03-1.pdf

Solo gestori archivio

Dimensione 86 kB
Formato Adobe PDF
86 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/165508
Citazioni
  • Scopus 75
  • ???jsp.display-item.citation.isi??? 67
Social impact